The details of how we developed the valuation are described in our Offering Memorandum posted to the About page of our campaign. See pages 18-19 of this document.

Hello Ritesh! Thanks for these questions, below are the answers: - While a study is mentioned, what is the long-term safety and efficacy data for Stone Stopper? Stone stopper's secret is the patented combination of the alkali citrate salts that provide the change in the urine chemistry comparable to the potassium citrate prescription without any side effects. The individual ingredients are not novel, they are FDA GRAS approved and have been used in 1000s of products in the US and globally for many decades. There is no concern about the safety of these ingredients. Regarding efficacy, Dr. Goldfarb wrote a white paper on the efficacy of alkali citrate to change urine chemistry in preventing kidney stones, citing 189 statistically valid clinical studies. The role of alkali citrate in the prevention of kidney stones is very well-studied and known to many healthcare practitioners. This is one of the reasons that over 65% of Moonstone customers are referred by their doctor. - How will Moonstone maintain its edge against established beverage/health food companies with larger resources? Who is your competition right now? Moonstone is the only OTC product on the market to deliver 30mEq of alkali citrate per serving; this is the equivalent of the potassium citrate prescription pill. No competitive product is currently available at retail that matches Moonstone Stone Stopper's efficacy and scientific backing. We continue to focus on HCP and customer outreach, building trust and credibility through product education. A variety of competitive products are available on ecommerce channels (Chanca Piedra/Stone Breaker, Kidney COP, Litholyte) but none delivers an effective does of alkali citrate per serving (30mEQ) and the majority are herbal solutions that lack scientific research to support efficacy. Stone Stopper's patented, alkali citrate formula is proven (with in-vivo studies) to change urine chemistry and prevent the crystallization of stones. - How will Moonstone ensure doctors recommend Stone Stopper over other options? One of our priorities is continued outreach to HCPs, including urologists, nephrologists, ER doctors, PCPs, nurses, PAs, and pharmacists. 65% of our customers were referred by their healthcare practitioner. We attend multiple conferences each year and have ongoing patient sampling programs, especially with urology and nephrology clinics.

Hello Olivier - thanks for your questions and your interest in Moonstone Nutrition. 2024 revenues are projected to be about $3 million. We are projecting revenues to reach over $75 million in the next 5 years. We are projecting positive cash flows in mid to late 2025. Our short-term debt includes a line of credit and loans from shareholders. The universities do not provide direct financial support to the company, but leading kidney stone doctors from the universities created and patented our formula and serve as advisors to the company. We have not gotten financial support from any notable angels yet. If you have more questions, feel free to join this week's live webinar Q&A sessions: Thursday, June 6 at 4pm ET. You can register for the webinar here: https://moonstonenutrition.com/pages/investment-opportunities?_kx=Ro-BPJ7UWZY4y1wq8QbmVg.RgYzrA

Hi Bill, great seeing you yesterday on our webinar, thanks for joining. I believe we answered all your questions yesterday during the live Q&A, but below are answers to the 3 questions you posted above. Question 1: Why it is you think that MoonStone is protected from other beverage/health food companies from entering the competition that can leverage their supply chain at potentially greater cost savings and higher profitability? Moonstone is not only a patented product, it is founded by the leading nephrologists and urologists from NYU, Harvard and UCSF. The product has been thoroughly studied in a clinical trial to be highly efficacious. The patent protection, the first mover advantage, the scientific credibility and an agile supply chain network are key to maintain dominance in the kidney stone prevention and kidney health category. The profitability is projected to increase further as we gain additional points of distribution. Question 2: To extent you view the competitive "moat" to be established by virtue of filed or pending patents, is this patent "wall" so extensive and distinct that you really think other competitors could not simply adjust the formulation and pursue other patents for the same product and target market? As mentioned above, patent protection is just one aspect of getting a competitive edge along with first mover advantage and scientific credibility. We believe the patent covers a broad range. It is always possible to create a product that is outside of the patent, however its effectiveness will always be questionable. In addition, we are actively looking at generating additional intellectual properties and patents for future products. Question 3: Lastly, what is are the "exit" propositions you are communicating to create value? Is it effectively towards an IPO? A private acquisition at an accretive share value, and if so do you plan to protect Class B investors form any dilutive terms on private acquisition? We think a private acquisition by a strategic investor is the most likely exit scenario, but we plan to explore all options available to maximize the exit return for all of our shareholders, including the Class B investors.

Hi Adam, thanks for your question. We always strive to provide all flavors in every product format. However, due to global supply chain challenges, many companies have faced unforeseeable disruptions. We have enhanced our planning process to minimize these disruptions to our customers. Our powder drinks are available in a variety of sizes: 7 packs, 15 packs, and 30-day bulk packs. We have ensured that each flavor has been available in at least 1 product format for our loyal customers. We expect to be fully stocked by early May. Many of our customers are referred by their doctors, so HCP outreach is crucial for us. We exhibit at many of the relevant conferences, including the AUA conference (American Urological Association), AAEM (American Academy of Emergency Medicine), along with other shows targeting nurses, family practitioners, pharmacists, nutritionists, and dieticians. We also have direct sampling programs with hundreds of doctors who trust Stone Stopper® and consistently recommend it to their patients.

Hello Viral, thank you for your questions. Question 1: It appears your product promotes alkalinization of urine, but doesn’t that depend on the type of Stone formed? Some stones require acidification vs alkalization of urine to prevent further stone development. How is this taken into account when the patients (majority) does not know what type of stones they are prone to develop? Almost all stones will respond to treatment with citrate supplementation, but alkalinization of the urine is not the only, or even the most important effect. Most stones are composed of calcium oxalate, and all calcium stones are inhibited by increasing urinary citrate excretion. In such cases, the increase in urine pH is an inevitable effect associated with more citrate in the urine. But the change in urine pH is not important for calcium oxalate stones. On the other hand, an increase in urine pH increases solubility of uric acid and cystine stones. Some controversy continues about the best treatment for relatively unusual calcium phosphate stones, which are about 15% of all stones. Does the increase in urine citrate inhibit these stones more than the increase in urine pH promote them? Dr. Goldfarb has argued that the inhibitory effect is much more important (https://pubmed.ncbi.nlm.nih.gov/22595827/) but no randomized trials have been performed; he would be happy to get into the details of this subject. Dr. Goldfarb will be at a Q&A session we are hosting this Thursday, April 18, at 4pm EST. Here is a link to that meeting, feel free to join: https://us02web.zoom.us/j/83980811341 The European guidelines on acidification of the urine for calcium phosphate stones are amazingly devoid of any real evidence. The idea that the amino acid methionine would be useful is completely unproven, and potentially adverse as acidification will lead to metabolic acidosis and potentially reduce bone mineral density. (https://pubmed.ncbi.nlm.nih.gov/23593205/). In summary, citrate supplementation with Moonstone Stone Stopper® will be associated with benefit for any kind of stone, except struvite (infection) stones. Such stones are best treated with surgical therapy and antibiotics. Stone Stopper® will not be adverse in such cases, as underlying disorders leading to calcium stones are often present in such patients.

Hi Bryce, thanks for your questions. 1. The increase in COGS is primarily due to an increase in product ingredients costs overall and an increase in the sales of gummies year over year. Gummies have a higher product cost than our other products, and gummies sales as a percentage of total sales increased to 9.1% in 2023 from 3.6% in 2022. 2. In 2023, ecommerce sales were approximately 85% of sales, and in-store retail sales were approximately 15% of sales. 3. Over the next 3-5 years, we expect distribution to shift to about 50% ecommerce and 50% in-store retail.